Torrent Pharmaceuticals Limited - Asset Resilience Ratio
Torrent Pharmaceuticals Limited (TORNTPHARM) has an Asset Resilience Ratio of 7.20% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read TORNTPHARM total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2025)
This chart shows how Torrent Pharmaceuticals Limited's Asset Resilience Ratio has changed over time. See Torrent Pharmaceuticals Limited shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Torrent Pharmaceuticals Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Torrent Pharmaceuticals Limited market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs7.05 Billion | 4.54% |
| Short-term Investments | Rs4.12 Billion | 2.66% |
| Total Liquid Assets | Rs11.17 Billion | 7.20% |
Asset Resilience Insights
- Limited Liquidity: Torrent Pharmaceuticals Limited maintains only 7.20% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Torrent Pharmaceuticals Limited Industry Peers by Asset Resilience Ratio
Compare Torrent Pharmaceuticals Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 1.96% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 8.47% |
Annual Asset Resilience Ratio for Torrent Pharmaceuticals Limited (2007–2025)
The table below shows the annual Asset Resilience Ratio data for Torrent Pharmaceuticals Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 2.31% | Rs3.46 Billion ≈ $37.42 Million |
Rs149.90 Billion ≈ $1.62 Billion |
-1.28pp |
| 2024-03-31 | 3.59% | Rs5.40 Billion ≈ $58.43 Million |
Rs150.61 Billion ≈ $1.63 Billion |
+1.16pp |
| 2023-03-31 | 2.43% | Rs3.65 Billion ≈ $39.47 Million |
Rs150.12 Billion ≈ $1.62 Billion |
+0.85pp |
| 2022-03-31 | 1.58% | Rs2.07 Billion ≈ $22.43 Million |
Rs131.00 Billion ≈ $1.42 Billion |
+0.30pp |
| 2021-03-31 | 1.28% | Rs1.80 Billion ≈ $19.51 Million |
Rs140.75 Billion ≈ $1.52 Billion |
-0.54pp |
| 2020-03-31 | 1.83% | Rs2.56 Billion ≈ $27.71 Million |
Rs140.38 Billion ≈ $1.52 Billion |
-2.55pp |
| 2019-03-31 | 4.37% | Rs6.17 Billion ≈ $66.75 Million |
Rs141.21 Billion ≈ $1.53 Billion |
-7.90pp |
| 2018-03-31 | 12.27% | Rs17.47 Billion ≈ $188.97 Million |
Rs142.43 Billion ≈ $1.54 Billion |
-7.78pp |
| 2017-03-31 | 20.05% | Rs20.30 Billion ≈ $219.55 Million |
Rs101.25 Billion ≈ $1.09 Billion |
+11.62pp |
| 2016-03-31 | 8.43% | Rs7.60 Billion ≈ $82.22 Million |
Rs90.14 Billion ≈ $974.79 Million |
+4.67pp |
| 2015-03-31 | 3.76% | Rs2.98 Billion ≈ $32.18 Million |
Rs79.11 Billion ≈ $855.55 Million |
+0.10pp |
| 2014-03-31 | 3.66% | Rs1.86 Billion ≈ $20.08 Million |
Rs50.70 Billion ≈ $548.28 Million |
+2.06pp |
| 2013-03-31 | 1.60% | Rs604.40 Million ≈ $6.54 Million |
Rs37.83 Billion ≈ $409.10 Million |
-1.22pp |
| 2012-03-31 | 2.81% | Rs865.16 Million ≈ $9.36 Million |
Rs30.74 Billion ≈ $332.39 Million |
-2.79pp |
| 2011-03-31 | 5.60% | Rs1.43 Billion ≈ $15.44 Million |
Rs25.48 Billion ≈ $275.60 Million |
-0.19pp |
| 2010-03-31 | 5.79% | Rs1.14 Billion ≈ $12.31 Million |
Rs19.65 Billion ≈ $212.52 Million |
-3.68pp |
| 2009-03-31 | 9.47% | Rs1.58 Billion ≈ $17.07 Million |
Rs16.67 Billion ≈ $180.33 Million |
+3.45pp |
| 2008-03-31 | 6.01% | Rs760.99 Million ≈ $8.23 Million |
Rs12.66 Billion ≈ $136.90 Million |
+0.91pp |
| 2007-03-31 | 5.11% | Rs533.55 Million ≈ $5.77 Million |
Rs10.45 Billion ≈ $113.01 Million |
-- |
About Torrent Pharmaceuticals Limited
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, marketing, and distribution of branded and generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including anti-diabetic, anti-microbial, cardiovascular, urology, gynecology, oncology, gastro-intestinal, nep… Read more